Poor sleep quality and reduced cognitive function in persons with heart failure

García, Sarah; Alosco, Michael L.; Spitznagel, Mary Beth; Cohen, Ronald A.; Raz, Naftali; Sweet, Lawrence H.; Colbert, Lisa H.; Hughes, Joel W.; Rosneck, Jim; Gunstad, John

doi:10.1016/j.ijcard.2012.01.037

Cited by 29 publications

(51 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…23,24 The patients grade their difficulties on a scale ranging from no problems (0), to very great problems (4). Using a summation score, insomnia can be subgrouped as no insomnia (0 -3), subclinical insomnia (4 -6), moderate insomnia (7 -9), and severe insomnia (10)(11)(12). Results have shown that MISS possesses adequate reliability and validity among the elderly.…”

Section: Sleep and Wake Patternmentioning

confidence: 99%

“…34 A scale ranging from not at all (0), to nearly every day (3) is used. The PHQ-9 can be subgrouped into no need of treatment for depression (0 -4), mild depression (5 -9), moderate depression (10)(11)(12)(13)(14), moderate to severe depression (15 -19), and severe depression (20 -27). The PHQ-9 has shown good diagnostic validity.…”

Section: Depression Patient Health Questionnairementioning

confidence: 99%

“…7,8 It has been described that elderly individuals with mild to moderate CHF often have a mild cognitive dysfunction. 9 Recent studies 8,10,11 in adults (mean age 62.8 years) with cardiovascular disease show that 'poor sleep' (i.e. global score ≥ 5 on the Pittsburgh Sleep Quality Index) is independently associated with reduced global cognitive function, 10 and executive functioning and attention.…”

Section: Introductionmentioning

confidence: 99%

“…global score ≥ 5 on the Pittsburgh Sleep Quality Index) is independently associated with reduced global cognitive function, 10 and executive functioning and attention. 11 Other studies 12,13,14 not focusing on CHF show that SDB-related hypoxia can be an indicator associated with cognitive dysfunction and dementia. Furthermore, reduced quality of life, anxiety, and depression have also been described.…”

Section: Introductionmentioning

confidence: 99%

“…Furthermore, reduced quality of life, anxiety, and depression have also been described. 11,15 Sleep disturbances, such as SDB, may from a pathophysiological perspective affect the development of early atherosclerosis (i.e. by an increased sympathetic activation), and as a consequence increase the risk of vascular dementia in patients with CHF.…”

Section: Introductionmentioning

confidence: 99%

See 4 more Smart Citations

Association between sleep‐disordered breathing, sleep–wake pattern, and cognitive impairment among patients with chronic heart failure

Hjelm

Strömberg

Årestedt

et al. 2013

European J of Heart Fail

View full text Add to dashboard Cite

AimsChronic heart failure (CHF) and sleep-disordered breathing (SDB) are often co-existing problems among the elderly. Apnoeic events may cause cognitive impairment. The aim of the study was to compare sleep and wake patterns, insomnia, daytime sleepiness, and cognitive function in community-dwelling CHF patients, with and without SDB, and to investigate the association between sleep-related factors and cognitive dysfunction. Methods and resultsIn this cross-sectional observational study, SDB was measured with an ApneaLink device and defined as an apnoeahypopnoea index (AHI) ≥15/h of sleep. Sleep and wake patterns were measured with actigraphy for 1 week. Insomnia was measured with the Minimal Insomnia Symptom Scale, daytime sleepiness with the Epworth Sleepiness Scale, and cognitive function with a neuropsychological test battery. A total of 137 patients (68% male, median age 72 years, 58% NYHA functional class II) were consecutively included. Forty-four per cent had SDB (AHI ≥15). The SDB group had significantly higher saturation time below 90%, more difficulties maintaining sleep, and lower levels of daytime sleepiness compared with the non-SDB group. Cognitive function and sleep and wake patterns did not differ between the SDB and the non-SDB group. Insomnia was associated with decreased global cognition. ConclusionThe prevalence of cognitive dysfunction was low in this population with predominantly mild to moderate CHF. This might have influenced the lack of associations between cognitive function and SDB. Insomnia was the only sleep-related factor significantly influencing cognition.--

show abstract

Section: Sleep and Wake Patternmentioning

confidence: 99%

Section: Depression Patient Health Questionnairementioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Association between sleep‐disordered breathing, sleep–wake pattern, and cognitive impairment among patients with chronic heart failure

Hjelm

Strömberg

Årestedt

et al. 2013

European J of Heart Fail

View full text Add to dashboard Cite

show abstract

Phosphodiesterase 1: A Unique Drug Target for Degenerative Diseases and Cognitive Dysfunction

Wennogle

Hoxie

Peng

et al. 2017

Advances in Neurobiology

View full text Add to dashboard Cite

The focus of this chapter is on the cyclic nucleotide phosphodiesterase 1 (PDE1) family. PDE1 is one member of the 11 PDE families (PDE 1-11). It is the only phosphodiesterase family that is calcium/calmodulin activated. As a result, whereas other families of PDEs 2-11 play a dominant role controlling basal levels of cyclic nucleotides, PDE1 is involved when intra-cellular calcium levels are elevated and, thus, has an "on demand" or activity-dependent involvement in the control of cyclic nucleotides in excitatory cells including neurons, cardiomyocytes and smooth muscle. As a Class 1 phosphodiesterase, PDE1 hydrolyzes the 3' bond of 3'-5'-cyclic nucleotides, cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP). Here, we review evidence for this family of enzymes as drug targets for development of therapies aimed to address disorders of the central nervous system (CNS) and of degenerative diseases. The chapter includes sections on the potential for cognitive enhancement in mental disorders, as well as a review of PDE1 enzyme structure, enzymology, tissue distribution, genomics, inhibitors, pharmacology, clinical trials, and therapeutic indications. Information is taken from public databases. A number of excellent reviews of the phosphodiesterase family have been written as well as reviews of the PDE1 family. References cited here are not comprehensive, rather pointing to major reviews and key publications.

show abstract